Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 417

Results For "CENT"

4823 News Found

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey
News | January 31, 2022

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey

In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21


Pharma industry seeks fiscal support to drive innovation
News | January 31, 2022

Pharma industry seeks fiscal support to drive innovation

Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India


USFDA approves Genentech’s Vabysmo to treat causes of vision loss
Drug Approval | January 31, 2022

USFDA approves Genentech’s Vabysmo to treat causes of vision loss

Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need


Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance
Hospitals | January 30, 2022

Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance

Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022


DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
News | January 29, 2022

DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine

Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission


Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate
Biotech | January 29, 2022

Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate

Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China


European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
Drug Approval | January 28, 2022

European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC

KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)


Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion
News | January 28, 2022

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion

The companies will continue with their exclusive agreements, including commercialization of their current portfolio


Moderna working on HIV vaccine antigens delivered through mRNA technology
Biotech | January 28, 2022

Moderna working on HIV vaccine antigens delivered through mRNA technology

The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology


Covaxin and Covishield granted conditional market approval
News | January 27, 2022

Covaxin and Covishield granted conditional market approval

The vaccines are currently only authorised for emergency use in the country